Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Non-Current Deffered Revenue (2021 - 2022)

Senti Biosciences has reported Non-Current Deffered Revenue over the past 2 years, most recently at $7.0 million for Q1 2022.

  • For Q1 2022, Non-Current Deffered Revenue changed N/A year-over-year to $7.0 million; the TTM value through Mar 2022 reached $7.0 million, changed N/A, while the annual FY2021 figure was $176000.0, N/A changed from the prior year.
  • Non-Current Deffered Revenue for Q1 2022 was $7.0 million at Senti Biosciences, up from $176000.0 in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $8.0 million in Q2 2021 and troughed at $176000.0 in Q4 2021.